行情

CLVS

CLVS

Clovis肿瘤药物
NASDAQ

实时行情|Nasdaq Last Sale

4.440
-0.130
-2.84%
盘后: 4.470 +0.03 +0.68% 18:48 09/21 EDT
开盘
4.570
昨收
4.570
最高
4.600
最低
4.400
成交量
310.52万
成交额
--
52周最高
11.10
52周最低
4.060
市值
5.26亿
市盈率(TTM)
-1.4040
分时
5日
1月
3月
1年
5年
HC Wainwright & Co. 维持对 Clovis Oncology 的买入,将目标价下调至 9 美元
HC Wainwright & Co. analyst Edward White maintains Clovis Oncology (NASDAQ:CLVS) with a Buy and lowers the price target from $10 to $9.
Benzinga · 17小时前
——HC Wainwright 将 Clovis Oncology 的目标价从 10 美元上调至 9 美元,维持买入评级
MT Newswires · 18小时前
到2026年,全球放射治疗市场预计将达到73亿美元,复合年增长率为4.2% - 财经新闻媒体
Palm Beach, FL - September 20, 2021 – FinancialNewsMedia.com News Commentary – Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective, low-c...
MENAFN · 1天前
到 2026 年,全球放射治疗市场预计将达到 73 亿美元,复合年增长率为 4.2%
PALM BEACH,  Fla., /PRNewswire/ -- Over the last decade, the radiotherapy devices market has seen significant technological advancements. These advancements have helped in the development of more effective, low-cost, and easy-to-use radiotherapy products ...
PR Newswire - PRF · 1天前
Clovis Oncology 退出剩余的 2021 年票据并通过其 ATM 股票发行计划筹集额外资金
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has paid off in full at maturity the remaining $64.4 million in principal amount outstanding of its 2.50% convertible senior notes due 2021. In addition, the
Benzinga · 1天前
非转移性去势抵抗性前列腺癌治疗市场-按制造商、业务分析、机会、行业增长和预测到 2029 年的概述
Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029"which delivers detailed overview of the global non-metastatic castration resistant prostate cancer treatment market in terms of market segmentation by therapy typ...
AmericaNewsHour · 1天前
助听技术 (HAT) 市场:按应用和地理趋势、增长、收入、市场影响和精确展望 2029 细分的主要国家
Research Nester released a report titled ": Global Demand Analysis & Opportunity Outlook 2029" which delivers detailed overview of the hearing assistive technology (HAT) market in terms of market segmentation by device type, device, application and region.
AmericaNewsHour · 6天前
克洛维斯 (CLVS) 自上次财报以来下跌 3.2%:能反弹吗?
Zacks.com · 09/03 15:31
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解CLVS最新的财务预测,通过CLVS每股收益,每股净资产,每股现金流等数据分析Clovis肿瘤药物近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CLVS价格均价为5.70,最高价位9.00,最低价为3.000。
EPS
机构持股
总机构数: 275
机构持股: 6,366.60万
持股比例: 53.77%
总股本: 1.18亿
类型机构数股数
增持
66
713.59万
建仓
25
136.39万
减持
30
168.86万
平仓
28
138.00万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+1.43%
制药与医学研究
+0.74%
高管信息
Non-Executive Chairman/Independent Director
Ginger Graham
President/Chief Executive Officer/Co-Founder/Director
Patrick Mahaffy
Co-Founder/Executive Vice President
Gillian Ivers - Read
Chief Financial Officer/Executive Vice President
Daniel Muehl
Executive Vice President/Chief Scientific Officer
Thomas Harding
Executive Vice President/General Counsel
Paul Gross
Executive Vice President/Director of Human Resources
Ann Bozeman
Executive Vice President
Lindsey Rolfe
Independent Director
Brian Atwood
Independent Director
Robert Azelby
Independent Director
James Blair
Independent Director
Richard Fair
Independent Director
Keith Flaherty
Independent Director
Paul Klingenstein
Independent Director
Edward Mckinley
Independent Director
Ronit Simantov
Independent Director
Thorlef Spickschen
暂无数据
CLVS 简况
Clovis Oncology, Inc.是一家生物制药公司,专注于在美国、欧洲和其他国际市场获得、开发和商业化抗癌药剂。该公司的产品Rubraca(rucaparib)是一种多聚腺苷二磷酸(ADP)-核糖聚合酶(PARP)的口服小分子抑制剂,在美国上市销售,用于复发上皮性卵巢癌和输卵管癌或原发性腹膜癌两种适应症。该公司还提供Lucitanib,它是一种口服的、研究性的以及有效的血管内皮生长因子受体1-3(VEGFR1-3)、血小板生长因子受体α和β以及成纤维细胞生长因子受体1-3(FGFR1-3)的酪氨酸激酶活性抑制剂。

微牛提供Clovis Oncology Inc(NASDAQ-CLVS)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CLVS股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CLVS股票基本功能。